Taipei Exchange Launches Dedicated Sustainable Bond Segment to Further Issuing Momentum
24.5.2021 12:00:00 EEST | Business Wire | Press release
The Taipei Exchange, TPEx, launched a dedicated segment for sustainable bonds, celebrating on May 18 with the debut of three social bond listings. The segment marks a milestone for Taiwan’s socially responsible investment and is in accordance with a plan announced by the Taiwanese government’s Financial Supervisory Commission (FSC). The commission’s plan, named the Green Finance Action Plan 2.0, was announced in August 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005043/en/
Taipei Exchange launches dedicated sustainable bond segment to further issuing momentum. (Graphic: Business Wire)
TPEx Chairman Philip Chen said in a statement announcing the new segment, “After accomplishing the mechanism regarding social bonds, the last piece of the puzzle, TPEx has integrated the regulations of Green Bonds, Sustainability Bonds, and Social Bonds and launched this segment exclusively for ESG concept bonds.” Chen went on to highlight TPEx’s market acclaim for launching Green Bond and Sustainability Bond operational directions in 2017 and 2020 respectively, which were in line with the ICMA’s GBP and SBG. The total outstanding amount of listed sustainable bonds has steadily grown, exceeding NT$207bn (US$7bn), according to Chen.
The first batch of three social bonds listed on TPEx is primarily funding socioeconomic advancement projects related to the global COVID-19 pandemic, projects such as increasing access to loans, providing job opportunities and raising the availability of affordable housing.
FSC Chairman Dr. Tien-Mu Huang said, “FSC fully supports financial innovation and product diversity. The Sustainable Bond Segment at TPEx provides the market with a clearer, more complete and consistent regulatory mechanism, facilitating easier compliance for issuers. This subsequently serves to direct funds to eco-friendly and socially beneficial projects, helping achieve the goals of Green Finance Action Plan 2.0 tremendously.” Mrs. Tania Berchem from the Luxemburg Trade and Investment Office in Taipei, Mr. Nicholas Pfaff from ICMA, and Mr. Sean Kidney from CBI all sent their congratulatory messages to TPEx for the dedicated segment.
Meanwhile, TPEx has modernized its sustainable bonds website (https://www.tpex.org.tw/web/bond/sustainability/index.php?l=en-us), improving all relevant information for clarity and accessibility. The updated website is bilingual, and key features have been added which include issuance status and bond framework information, assessment opinions from external reviewers, market reports, and access to current sustainability studies and research reports. Speaking of the new website, Chen added, “In facilitating responsible investing, we hope to offer a full array of information to enhance transparency while simultaneously raising investors’ social awareness.”
About the Taipei Exchange
Established in 1994, the Taipei Exchange is a member of the World Federation of Exchanges. The exchange has grown with a vision of sustainability to meet the diverse needs of issuers and investors, and has long been dedicated to fostering emerging, high-tech and creative industries by providing a viable channel for raising capital. The exchange has also established a fast-growing bond market. For more information, visit: https://www.tpex.org.tw/web/index.php?l=en-us
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005043/en/
Contact information
Tinna Chen: tinnachen@tpex.org.tw
Iris Yang: irisyang@tpex.org.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom